**I was delighted to participate as a speaker and panel discussant at the 2018 American Conference on Pharmacometrics in a session devoted to dialogue between "pharmacometric modelers" and "statisticians." In the current perspective, I reprise the major points of my talk, which addressed the possibility of drawing valid causal inferences from observational data. I augment this reprise with brief remarks comparing diagrammatic conventions in pharmacometrics to those used in formal causal diagrams.**

The Causeway {#psp412395-sec-0002}
============

The 2018 American Conference on Pharmacometrics was held on the narrow sand spit that connects Coronado Island to Imperial Beach on the mainland; in other words, on a causeway. I want to begin by expressing the hope that the burgeoning field of causal inference will come to provide a metaphorical causeway (or "cause‐way"!), bridging fundamental perspectival gaps between the disciplines of pharmacometrics and statistics.

G‐computation and Pharmacometric Population Simulation {#psp412395-sec-0003}
======================================================

In my talk I suggested, albeit with caveats, that a treatment effect estimate derived from pharmacometric population simulation will generally have a causal interpretation that is rigorously defensible, even when the treatments being compared (e.g., high exposure vs. low exposure) have not been randomized. I supported this claim by showing that pharmacometric population simulation generally relies on the same logic as the causal inference procedure known as G‐computation,[1](#psp412395-bib-0001){ref-type="ref"} and the latter procedure is known to produce valid causal estimates under assumptions that can be fully formalized and articulated.

I developed my argument with reference to kidney stone surgery data published by Charig *et al*.[2](#psp412395-bib-0002){ref-type="ref"} The comparison of open surgery to percutaneous nephrolithotomy based on those data has become a classic known in statistical discussions as "Simpson\'s paradox."[3](#psp412395-bib-0003){ref-type="ref"} The "paradox" manifests in that case as a conflict between a misleading overall analysis, which seems to favor percutaneous nephrolithotomy and subset analyses that clearly favor open surgery. This phenomenon, which is exceedingly unlikely in randomized experiments, is readily explained in terms of confounding when treatment is not randomized. The data therefore provide a simple and standard test case for causal inference procedures: if an analysis methodology avoids the misleading inference associated with the naive "overall" analysis of those data, that is a good sign.

In my talk, I proposed that a normative pharmacometric approach to these data would rely on population simulation, proceeding as follows:

*Modeling*. In the present example, I assumed that a "typical" (diligent) pharmacometrician would identify kidney stone size as an important variable for understanding variation in the outcome. In the language of the G‐computation and targeted maximum likelihood literature, this amounts to an assumption that pharmacometricians will generally develop an adequate Q‐model.[4](#psp412395-bib-0004){ref-type="ref"}*Simulation*. I then proposed that the "typical" pharmacometrician, having developed a response model in the manner described previously, would proceed to estimating the treatment effect via "population simulation" using a recipe similar to the following:2.1.Programmatically generate a large (e.g., *n* = 1,000) virtual population by resampling covariate values from the empirical distribution. (In this simple example, resampling is equivalent to parametric Bernoulli sampling, but the intention here is to hew as closely as possible to a typical pharmacometric workflow.)2.2.For every patient in the virtual population, fix treatment at one level, e.g., "open surgery."2.3.Use the estimated‐response model to simulate a response value for each member of the virtual population as a function of that patient\'s covariate values (in this example, kidney stone size) and treatment assignment.2.4.Compute the average probability of success in the simulated population.2.5.Repeat all of the above steps, replacing the treatment in step 2.2 with the comparative intervention (in this example, "percutaneous nephrolithotomy").2.6.Compare the probability estimates obtained in the two iterations of step 2.5 to obtain the effect estimate.

An R script to recreate the relevant subset of the Charig *et al*. data and to implement the analysis described previously is provided as [**Supplemental Material**](#psp412395-sup-0001){ref-type="supplementary-material"}.

For purposes of this article, the differences between G‐computation and pharmacometric population simulation are not as important as their similarities. Nonetheless, the connection between the two procedures is perhaps more obvious if one briefly explores the major differences: In G‐computation, step 2.1 of the previous procedure would not involve resampling to create a large "virtual population" but would instead involve the creation of a "virtual sample," having exactly the same sample size and exactly the same covariate distribution as in the original data setIn G‐computation, step 2.3 of the previous procedure would not involve the introduction of stochastic elements and would replace the simulated responses with conditional predictions of the response

These two differences are motivated by the same consideration, namely, that pharmacometric response models are typically nonlinear mixed‐effects models for which predicted values are not directly available as a function of model parameters. In that context, for every covariate combination present in the original data, one wants to generate multiple draws from the random effect distribution to arrive at simulation‐based estimates of the predicted response that properly average over the random‐effect distribution.

Notwithstanding these relatively minor differences in procedures, G‐computation and pharmacometric population simulation share an implicit invocation of what Pearl *et al*.^5^ simply call "the adjustment formula."[5](#psp412395-bib-0005){ref-type="ref"} From a purely probabilistic perspective, this is nothing more than applying the law of total probability to average conditional response distributions with respect to a covariate distribution.

Causal Concepts and Causal Diagrams {#psp412395-sec-0004}
===================================

As the previous example is intended to illustrate, it would hardly be novel to propose that the law of total probability be applied in the context of pharmacometric simulation to properly average over covariate distributions. Moreover, to do so would be to merely advance various probabilistic and statistical methods, which misses the point of formal causal reasoning entirely. What is ultimately on offer from the causal inference literature is not merely a new arsenal of statistical techniques but rather a language and a set of formalisms to represent concepts that cannot be reduced to probabilistic and statistical concepts.[5](#psp412395-bib-0005){ref-type="ref"}, [6](#psp412395-bib-0006){ref-type="ref"}

Formalisms associated with causal diagrams provide a major case in point. At the probabilistic level of analysis, the simple graph "oral dose → plasma concentration ← intravenous dose" implies that the joint distribution of the three variables can be specified in terms of the joint marginal distribution of the dose variables and the conditional distribution of plasma concentration given the levels of the two dose variables. Of course, that much could be said of any three random variables; it is trivially true, so the graph fails to convey any nontrivial semantic content as long as it is interpreted through that exclusively probabilistic lens. When interpreted through that lens it does not tell us what would happen to oral dose if we exogenously intervened to manipulate intravenous dose. By contrast, we associate causal semantics with the graph if and only if we stake out positions regarding the effects of (perhaps hypothetical) interventions on the represented variables.

One may object that such graphs are also nothing new in pharmacometrics: typical graphical representations of pharmacometric models (for example, the graphical representations presented by Mager *et al*.[7](#psp412395-bib-0007){ref-type="ref"}) are clearly meant to convey implications about interventions and are interpreted as such. This is only partly true, and for pharmacometrics to harvest the fruits of causal diagram research it remains to systematically compare the (seemingly unarticulated) "rules" for interpretation of pharmacometric model diagrams to the rigorously articulated rules for interpretation of causal diagrams. As an example of the differing semantics, note that in a typical pharmacometric diagram such as **Figure ** [1](#psp412395-fig-0001){ref-type="fig"} **a**, the arrows associated with clearance of the drug (labeled CL and CL~E~) do not denote causal influence on graphical descendants (in fact the descendants are not even articulated) but rather, the longitudinal progression of the nodes from which they emanate. In contrast, the strict application of causal diagram principles would dictate that arrows only be used to represent causal influence, in which case temporal evolution would need to be represented in some other fashion (e.g., by indexing variables by time in a discrete‐time approximation, as in **Figure ** [1](#psp412395-fig-0001){ref-type="fig"} **b**). Indeed, at present, a substantial barrier to the application of causal diagram methodologies in pharmacometrics is the underdevelopment of causal diagram techniques for continuous‐time dynamic systems. The development of a hybrid graphical system that would support the formal operations that pertain to causal diagrams without losing the representational economy of conventional pharmacometric diagrams would appear to be a worthwhile objective for future research.

![Comparison of diagrammatic conventions used in pharmacometrics as compared to those used in the causal inference literature. The same simple biophase dsitribution model is represented in both cases. When using pharmacometric conventions (**a**), arrows do not merely convey information about the causal effects of nodes on other nodes. In this case the arrows associated with clearance (CL and CL_E) also convey information about the temporal evolution of the system. By contrast, arrows in the causal diagram (**b**) represent causal influence only. The latter constraint forces one to represent the continuous time system as a discrete approximation, perhaps suggesting the need for a hybrid representational system.](PSP4-8-253-g001){#psp412395-fig-0001}

Although it is not yet clear how to marry the two graphical ecosystems, the potential progeny of such a marriage seem worth fighting for. In my talk, I reviewed a simplified adaptation of the gamma‐glutamyl transpeptidase system example discussed by Daniel *et al*.,[8](#psp412395-bib-0008){ref-type="ref"} as shown in **Figure ** [2](#psp412395-fig-0002){ref-type="fig"} **a**. In the context of this example, I illustrated the value of what Pearl *et al*.^5^ call "graph surgery" as a means of formalizing the causal questions of interest and simultaneously clarifying the simulation logic that should be implemented to address such questions (see **Figure ** [2](#psp412395-fig-0002){ref-type="fig"} **b,c**).

![Use of graph surgery to represent causal questions and specify simulation logic, based on a simplified version of the gamma‐glutamyl transpeptidase system evaluated by Daniel et al. This example assumes that observations are available only from the system \"in the wild\", i.e. in the absence of any randomized intervention (**a**). Variables represented are: alcohol consumption (ALC), body mass index (BMI), gamma‐glutamyl transpeptidase levels (GGT), systolic blood pressure (SBP), and socioeconomic status (SE). Assuming a statistical model can be developed to characterize the joint distribution of the variables in this observational system, simulation from such a model can then follow the logic implied by the "graph surgeries" of b,c to answer causal questions. The total causal effect of alcohol consumption, such as would be of interest if a policy or lifestyle intervention were being considered to limit alcohol consumption, is formalized by this first graph surgery (**b**). The surgically modified graph uses the "do" operator from Pearl et al. 5 to offer a complete specification of the causal question while providing a visual roadmap for the simulation logic that should be implemented to answer the question. The causal effect of GGT, such as would be of interest if GGT were a pharmacologic target under consideration, is formalized in the second graph surgery (**c**).](PSP4-8-253-g002){#psp412395-fig-0002}

Finding Common Cause in Our Past {#psp412395-sec-0005}
================================

Both my podium presentation and my summary here have borrowed heavily from Pearl and Mackenzie\'s *The Book of Why*.^6^ In closing, I would like to briefly call attention to one important aspect of that book that I did not broach in my talk: the historical provenance of statisticians' beliefs and attitudes with regard to causality. In reading the narrative of that history by Pearl and Mackenzie, I was struck by how many of the familiar antagonisms between the "pharmacometric modeler" community and the "statistics" community are explicable in terms of the contentious battles over the meaning of causality in the last two and a half centuries, battles that can be traced back (at least) to the pivots in thinking that occurred during the Age of Enlightenment. For anyone seeking to advance the field of pharmacometrics via dialogue with the statistical community, this history is no mere curiosity. The more we understand the historical forces that have shaped our differing perspectives, the more we are likely to find a causeway of common ground. That would be cause to celebrate!
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**Supplementary Material.** An annotated R script illustrating pharmacometric population simulation as a causal inference procedure
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Click here for additional data file.
